Objective: Reports on zonisamide monotherapy are limited despite favourable preliminary data, and typically restricted to tertiary referral centres. The goal of this study is to report clinical experience with zonisamide monotherapy in a large, multi-group clinic setting. Methods: We reviewed the charts of patients treated with zonisamide monotherapy in the Neurology Department of the Kelsey-Seybold Clinic (Houston, Texas) during an 18-month period. We analysed subgroups of patients who were naive to antiepileptic drug (AED) therapy (Group 1) and those who had previous exposure to AEDs (Group 2). Results: The study included 54 paediatric and adult patients with a variety of seizure types: 15 patients in Group 1 and 39 patients in Group 2. Mean maintenance zonisamide dosages in the two groups were similar (193 mg/day in Group 1 vs. 218 mg/day in Group 2). Thirty-eight patients (70.4%) continued zonisamide monotherapy, with 7 patients (13.0%) adding a second AED and 9 patients (16.7%) switching to a different drug. Of the 24 patients who became seizure free on zonisamide monotherapy, 11 were on the 100-mg initial dosage. Zonisamide monotherapy was well tolerated. Conclusions: Zonisamide monotherapy is safe and effective for a variety of seizure types and may be appropriate as first-line therapy in some cases.
INTRODUCTION
The objective of pharmacotherapy for epilepsy is to achieve maximum efficacy (seizure freedom) with minimal or no adverse events (AEs). This goal is best achieved using as few drugs as possible at the lowest dosages needed for effective seizure management. Although polypharmacy may be required for some patients to maintain acceptable seizure control, it is often unnecessary and sometimes detrimental. Shorvon and Reynolds 1 successfully reduced polypharmacy to monotherapy in 29 of 40 consecutive epilepsy patients, often noting a decrease in seizure frequency and/or improvement in cognitive function from the previous year during which the subjects were on polypharmacy. Ludgate et al. 2 showed that a reduction from polypharmacy to monotherapy or reduced polypharmacy (i.e. fewer drugs) was associated with significantly better scores on several psychometric tests. Although these studies were done before the introduction of several of the newer antiepileptic drugs (AEDs), some of the older and newer drugs currently in use are associated with significant cognitive AEs 3 .
Zonisamide, a newer AED with multiple mechanisms of action, has demonstrated efficacy as an adjunctive agent in clinical trials [4] [5] [6] . The drug is indicated as an adjunctive therapy for partial seizures in adults, but has been used in Japan since 1989 and in the United States since 2000 for a variety of seizure types in both adult and paediatric epilepsy patients. Zonisamide monotherapy has been used successfully in Japan for a number of years 7 . Recently, there have been reports from Japan 8 and the United States 9 of zonisamide monotherapy for infantile spasms. For the most part, however, North American experience with zonisamide monotherapy is limited and usually restricted to tertiary referral centres. Here, we report our experience with zonisamide monotherapy in the neurology department of a large, multi-group clinic.
METHODS
This chart review included all patients who received zonisamide as monotherapy in the Neurology Department of the Kelsey-Seybold Clinic (Houston, Texas) between 1 April 2001 and 30 September 2002. Charts were reviewed for patient demographic data, seizure types, previous AED exposure, zonisamide dosage, duration of treatment and clinical outcome. For the purposes of this analysis, patients were divided into two groups: those for whom zonisamide monotherapy was their first treatment with an AED (Group 1) and those who initiated zonisamide monotherapy after discontinuing other AEDs (Group 2).
RESULTS
Fifty-four patients were treated with zonisamide monotherapy during the 18-month study period: 15 in Group 1 and 39 in Group 2. Most patients in Group 2 had discontinued their previous AED therapy due to lack of efficacy (19 patients) or AEs (18 patients). One patient was switched to zonisamide after receiving a different AED in the emergency department, and one had been seizure free for more than 2 years without pharmacotherapy but was started on zonisamide after seizure recurrence. Patient demographics and seizure types are presented in Table 1 .
Patients in Group 1 were maintained on zonisamide dosages of 100-400 mg/day, with a mean dosage of 193 mg/day. Patients in Group 2 received dosages of 100-500 mg/day, with a mean dosage of 218 mg/day. Overall, 20 patients (37.0%) were maintained on the initial dosage of 100 mg/day.
During the study period, 23 patients (42.6%) received zonisamide monotherapy for less than 6 months, 21 patients (38.9%) for 6-12 months and 10 patients (18.5%) for longer than 12 months. Thirtyeight patients (70.4%) continued zonisamide mono- (Table 2) . Seven patients (13.0%) added a second AED, and 9 patients (16.7%) replaced zonisamide with another AED. Reasons for zonisamide discontinuation included recurrent seizures (2 patients), headache, body ache, anxiety, memory problems, and drowsiness (1 patient each), with 2 patients discontinuing against medical advice because they did not want to take any medications. No serious AEs were noted. A total of 24 patients (44.4%) were seizure free for at least 6 months on zonisamide monotherapy. Of these, 11 (45.8% of seizure-free patients, 20.4% of all patients) were seizure free on the initial dosage of 100 mg/day (Table 3) . Four patients in Group 1 and 10 patients in Group 2 were seizure free for 6-12 months. Two patients in Group 1 and 8 patients in Group 2 were seizure free for more than 1 year. Seizure frequency data for patients who did not achieve seizure freedom were not available.
DISCUSSION
Clinical studies have shown that a reduction in polypharmacy may improve patient care. In particular, some patients experience improved seizure control 1 and/or fewer cognitive and behavioural AEs 1, 2 on monotherapy than with multiple drugs. An additional advantage of monotherapy is that potential interactions between AEDs do not complicate the choice of medications. Zonisamide is a logical choice to initiate monotherapy because it does not inhibit or induce cytochrome P450 enzymes 3, 5 , and therefore will not interfere with the metabolism of potential add-on drugs, should they become necessary. However, the potential effect of add-on drugs on zonisamide concentrations merits consideration. Furthermore, zonisamide can be given once a day 5 , which improves compliance 10 .
The results of our 18-month study in the neurology department of a large, multi-group clinic indicate that zonisamide monotherapy is safe and effective, either as first-line therapy or for patients who experience poor seizure control or intolerable AEs with other AEDs. The mean dosage in patients with previous AED exposure was slightly higher than that of AED-naive patients, possibly because AED-refractory patients may have epilepsies that are more difficult to treat with low dosages. However, 20% of patients in the study were seizure free at the 100-mg/day introductory dosage. Our experience suggests that zonisamide monotherapy is a viable option for many epilepsy patients, and may be a reasonable choice for first-line therapy in some cases.
